One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Issue Information
doi : 10.1111/jdv.20119
Journal of the European Academy of Dermatology and Venereology: Volume 39, Issue 6
Doxycycline for sexually transmitted infections' prevention: Balancing promise and public health concerns
doi : 10.1111/jdv.20690
Less can be more: The case for extended dosing intervals in biologic therapy for AD
doi : 10.1111/jdv.20684
Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
doi : 10.1111/jdv.20691
Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
doi : 10.1111/jdv.20693
Oral health care pathways for patients with epidermolysis bullosa: A position statement from the European reference network for rare skin diseases
doi : 10.1111/jdv.20498
Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how?
doi : 10.1111/jdv.20534
Hand eczema and changes in the skin microbiome after 2 weeks of topical corticosteroid treatment
doi : 10.1111/jdv.20366
Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2)
doi : 10.1111/jdv.20388
Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
doi : 10.1111/jdv.20372
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study
doi : 10.1111/jdv.20312
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study
doi : 10.1111/jdv.20526
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
doi : 10.1111/jdv.20547
Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study
doi : 10.1111/jdv.20605
An international survey of recalcitrant and recurrent tinea of the glabrous skin—A potential indicator of antifungal resistance
doi : 10.1111/jdv.20146
Corrigendum to ‘Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis’
doi : 10.1111/jdv.20683
Enhancement of sun-damaged skin qualities with tirbanibulin: AÂ prospective Phase 4 study (SunDamage Study)
doi : 10.1111/jdv.20416
Disagreement between physicians' and patients' assessment of disease activity in psoriasis: The SPEECH registry study
doi : 10.1111/jdv.20428
Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN-FRT evaluation
doi : 10.1111/jdv.20432
Clinical characteristics of iatrogenic versus idiopathic linear IgA bullous dermatosis: A systematic review
doi : 10.1111/jdv.20429
Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules
doi : 10.1111/jdv.20413
Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption
doi : 10.1111/jdv.20420
Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year
doi : 10.1111/jdv.20334
Genetic association of maternal smoking around birth with psoriasis: A two-sample Mendelian randomization analysis
doi : 10.1111/jdv.20410
Association of obesity with inflammatory skin disease: An inpatient population study
doi : 10.1111/jdv.20440
Lewis blood group antigens and ABH secretor status in patients with pemphigus
doi : 10.1111/jdv.20454
AI versus dermatologist performance in psoriasis body surface area assessment: A ground truth-validated, anatomical segment-based comparative study (AI PASS)
doi : 10.1111/jdv.20456
Comparative analysis of temperature-controlled cryotherapy versus intralesional triamcinolone acetonide injection for alopecia areata: An intrasubject split-lesion pilot study
doi : 10.1111/jdv.20464
Bimatoprost for the management of vitiligo: A systematic review and meta-analysis
doi : 10.1111/jdv.20458
Dermatological societies and their climate change and sustainability commitment through 2024
doi : 10.1111/jdv.20488
Infections and genotypes of Chlamydia trachomatis among men who have sex with men in China: A nationwide community-based study
doi : 10.1111/jdv.20487
Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: Evaluation from the French healthcare system
doi : 10.1111/jdv.20497
Spesolimab in refractory paediatric acrodermatitis continua of Hallopeau, a case series
doi : 10.1111/jdv.20500
Napkin psoriasis and the risk of later psoriasis development: A single-centre retrospective study
doi : 10.1111/jdv.20513
Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study
doi : 10.1111/jdv.20516
Mycobacterium chelonae cutaneous infections unrelated to invasive procedures: A multicentre retrospective case series
doi : 10.1111/jdv.20521
The impact of dupilumab on sleep disruptions in patients with prurigo nodularis: A systematic review and meta analysis
doi : 10.1111/jdv.20495
Recibokibart, an anti-IL-36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
doi : 10.1111/jdv.20511
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
doi : 10.1111/jdv.20568
Sentinel lymph node biopsy may no longer be a critical component of melanoma management
doi : 10.1111/jdv.20349
Reply to: Oral dutasteride is a first-line treatment for frontal fibrosing alopecia – There is insufficient evidence to recommend dutasteride as first-line treatment in frontal fibrosing alopecia
doi : 10.1111/jdv.20417
Oral dutasteride can be considered a first-line treatment for frontal fibrosing alopecia until high-quality clinical trials could show better results with other therapies
doi : 10.1111/jdv.20566
Concerns regarding the systematic review and editorial on oral dutasteride for frontal fibrosing alopecia
doi : 10.1111/jdv.20530
Towards a more comprehensive evaluation: Addressing limitations in the study of dupilumab and pregnancy outcomes
doi : 10.1111/jdv.20572
Reply to ‘EuroGuiderm Guideline on lichen sclerosus-introduction into lichen sclerosus’
doi : 10.1111/jdv.20612
Reply to ‘EuroGuiderm guideline on lichen sclerosus—Treatment of lichen sclerosus’
doi : 10.1111/jdv.20596
